Oncolytic CDMO Services
End-to-end development and GMP manufacturing of oncolytic viruses for next-generation cancer therapies.
Overview
At Elise Biopharma, we provide comprehensive CDMO services for the development and manufacture of oncolytic viruses (OVs)—a rapidly advancing class of immuno-oncology therapeutics. From vaccinia and HSV to adenovirus and novel engineered backbones, we support innovators developing viruses that selectively infect and lyse tumor cells while stimulating anti-tumor immunity.
Our capabilities cover the entire pipeline: cell line engineering, upstream amplification, downstream purification, QC and characterization, regulatory dossier preparation, and GMP fill-finish. With integrated process development suites and commercial-scale GMP manufacturing, Elise Biopharma offers a turnkey path from discovery through clinical and commercial supply.
Oncolytic viruses are among the most promising yet technically demanding modalities. They combine the complexity of live viral biologics with the stringency of oncology programs. We understand the challenges—lot consistency, genetic stability, tumor-selective potency, viral clearance, and regulatory scrutiny—and have built our infrastructure to solve them.
Why Oncolytic Viruses Matter
Oncolytic virotherapy is not new—the concept was first observed over a century ago—but only in the past decade have genetic engineering and advanced manufacturing enabled OVs to enter mainstream pipelines. Today, OVs are being designed to:
- Directly lyse tumor cells through selective viral replication.
- Release tumor-associated antigens (TAAs) to prime systemic anti-tumor immunity.
- Deliver therapeutic payloads (cytokines, checkpoint inhibitors, immune modulators) directly to the tumor microenvironment.
- Synergize with standard-of-care chemotherapy, radiotherapy, and checkpoint blockade.
Dozens of OV programs are advancing globally, with approvals already achieved (e.g., T-VEC) and many in mid-to-late clinical stages. The opportunity is massive—but requires specialized CDMOs that can handle live viral vectors under GMP, deliver clinical-grade potency and consistency, and support regulatory filings in oncology’s most demanding space.
A Trusted Partner for Oncolytic Virus Innovators
We partner with companies across the spectrum of OV development:
- Biotech startups engineering novel viral backbones or payload-armed OVs.
- Biopharma companies expanding immuno-oncology portfolios into viral modalities.
- Academic spinouts translating OV discoveries into first-in-human trials.
- Global pharma leaders outsourcing specialized viral manufacturing capacity.
- Translational consortia seeking GMP supply for investigator-initiated studies.
Our Oncolytic Virus CDMO Capabilities
Vector Platforms
We support a broad range of OV backbones, including:
- Vaccinia virus – Large genome, high payload capacity, rapid cytolysis.
- Herpes simplex virus (HSV-1, HSV-2) – Strong tumor selectivity, payload versatility, and established regulatory precedent.
- Adenovirus (Ad5, Ad11, engineered serotypes) – High infection efficiency, scalable production, and immune-stimulating properties.
- Measles virus – Potent tumor lysis, synergy with immune checkpoint blockade.
- Novel or engineered backbones – Custom platforms with synthetic biology-driven modifications for tumor selectivity, safety, and immunogenicity.
Process Development
Our end-to-end process development suite covers:
- Cell line engineering – Master cell banks, CRISPR-engineered hosts for viral amplification, serum-free adapted lines for GMP.
- Upstream amplification – Suspension and adherent cell platforms, single-use bioreactors (2 L–2,000 L), controlled MOI and replication kinetics.
- Downstream purification – Tangential-flow filtration, chromatography (ion-exchange, size-exclusion, affinity), density gradient centrifugation.
- Stability optimization – Formulation strategies for long-term storage and transport.
Analytical & QC Expertise
Oncolytic viruses require robust QC to satisfy regulatory agencies. Elise Biopharma provides:
- Genetic stability assays – NGS and qPCR-based verification of viral genome integrity.
- Potency assays – In vitro cytolysis assays across tumor cell lines; plaque assays; transgene expression quantification.
- Infectivity & replication – MOI determination, burst size analysis, replication competence.
- Safety assays – Residual host DNA, residual proteins, adventitious agent testing, replication control.
- Immunological profiling – Cytokine release, T-cell activation, and in vivo tumor efficacy studies through partner CROs.
Formulation & Fill-Finish
We offer specialized formulation services for OVs:
- Cryopreservation and LN₂ logistics for global trial deployment.
- Buffer optimization for stability without loss of infectivity.
- Lyophilized formulations under development for specific OV platforms.
- Fill-finish in vials, syringes, or cartridges under Grade A isolators.
Scale-Up & GMP Manufacturing
We provide seamless scale-up from discovery to commercial readiness:
- Bench-scale – 2 L, 10 L, 20 L development batches.
- Pilot scale – 50–200 L engineering runs for process optimization.
- GMP suites – 500–2,000 L production with validated consistency.
- Commercial readiness – Integrated planning, COGs modeling, supply chain and cold-chain logistics.
Regulatory & Clinical Support
Oncolytic viruses sit at the intersection of viral vector manufacturing and oncology biologics—both heavily regulated. Elise Biopharma provides:
- CMC documentation for IND, CTA, and BLA submissions.
- Global regulatory alignment with FDA, EMA, PMDA, NMPA frameworks.
- Stage-appropriate documentation – early-phase exploratory filings through to late-stage commercial dossiers.
- Traceability and QMS aligned with ICH Q5, Q6, and oncology-specific requirements.
- Tech transfer & lifecycle support – ensuring seamless movement from clinical to commercial facilities.
Innovation & Differentiation
Elise Biopharma is built to handle complexity at scale:
- Single-use bioreactor platforms for flexibility across OV backbones.
- Digital-twin process modeling for predictive scale-up.
- Advanced analytics – NGS, TEM imaging, SPR/BLI, and functional potency assays in-house.
- Integrated services – discovery support, process development, GMP production, QC, and regulatory consulting.
- Global reach – logistics and regulatory support for multi-region trial deployment.
Why Innovators Choose Elise Biopharma
Clients choose Elise because we combine:
- Deep expertise in viral vector manufacturing with oncology program literacy.
- Flexible capacity from 2 L R&D to 2,000 L GMP.
- Speed to clinic through parallelized development and GMP readiness.
- Assay innovation for potency, safety, and immunogenicity.
- Global regulatory literacy across all major oncology markets.
Whether you are building a next-generation vaccinia, an HSV armed with cytokine payloads, or a novel engineered adenovirus, Elise Biopharma provides the scale, rigor, and speed to bring your oncolytic virus program to patients.
Closing thoughts on Oncolytic Viruses
Oncolytic viruses represent one of the most exciting frontiers in immuno-oncology. But their complexity demands a CDMO partner capable of managing viral biology, oncology regulatory frameworks, and GMP-grade manufacturing under one roof. At Elise Biopharma, we deliver that integration—turning OV programs into clinical and commercial realities.
Contact us today to discuss your oncolytic virus project and explore how Elise Biopharma can accelerate your path to the clinic.
Email our team at info@elisebiopharma.com.